RxDoctor Payments DataLook up a doctor →

Arthur Itkin, MD

Neurology · Palos Heights, ILNPI 1184634974

Payments from drug & device makers

$808,348in general payments, 2019–2025

Across 1,748 payments — averaging $462.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$221K
  • Sanofi$152K
  • Amgen$86K
  • MDD US Operations, LLC$81K
  • Mallinckrodt Hospital Products Inc.$63K
  • EMD Serono, Inc.$46K
  • plus $160K from 35 others

What the payments were for

  • Consulting fees$34,0934%
  • Speaking & faculty fees$706,70587%
  • Travel & lodging$37,7665%
  • Food & beverage$29,7024%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808,348 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$601,525
Medicare patients
723
Services billed
50,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$738,124
CopaxoneGlatiramer Acetate55$414,255
ZeposiaOzanimod Hydrochloride32$287,808
FingolimodFingolimod Hcl33$250,854
MayzentSiponimod13$237,919
Kesimpta PenOfatumumab19$182,689
Rebif RebidoseInterferon Beta-1a/Albumin15$157,886
TecfideraDimethyl Fumarate22$144,484
Dimethyl Fumarate20$128,409
Dalfampridine ErDalfampridine197$115,994
BetaseronInterferon Beta-1b12$114,010
AmpyraDalfampridine13$91,588
Aimovig AutoinjectorErenumab-Aooe87$67,876
GlatopaGlatiramer Acetate15$61,577
Teriflunomide48$47,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$32,737$414,25555 claims
E.r. Squibb & Sons, L.L.C.Zeposia$42,982$287,80832 claims
NovartisMayzent$20,927$237,91913 claims
BiogenTecfidera$7,057$144,48422 claims
Acorda Therapeutics, IncAmpyra$130$91,58813 claims
AbbVieUbrelvy$220,930$33,87223 claims
PfizerNurtec Odt$179$29,55919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.

Other neurology in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →